IL1B and atherosclerosis: Inflammation is a hallmark of atherosclerosis (171), and a recent clinical trial, The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS), for the first time showed in a proof-of-concept trial that inhibiting inflammation using an antibody against Il-1β decreased cardiovascular events (172).